Broderick Eaton, DO
Family Medicine · Wynne, ARNPI 1992115646
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,013 of the $49,148 with a category attached, or 89.6%. Amgen accounts for 96.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $22,053 and has fallen 53.2% since, to $10,319 in 2025. Among family medicine clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $264.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$47K
- Novo Nordisk$277
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$258
- AstraZeneca$241
- Boehringer Ingelheim$226
- GSK$174
- plus $699 from 21 others
Across 60 payments — averaging $6539.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$355K
- GSK$38K
What the payments were for
- Speaking & faculty fees$44,01390%
- Travel & lodging$2,3055%
- Food & beverage$2,8316%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 74 | $47,273 |
| Novo Nordisk | 13 | $277 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $258 |
| AstraZeneca | 17 | $241 |
| Boehringer Ingelheim | 16 | $226 |
| GSK | 11 | $174 |
| Pfizer | 5 | $99 |
| Johnson & Johnson | 6 | $92 |
| Merck | 6 | $91 |
| Ultragenyx Pharmaceutical Inc. | 3 | $46 |
| Novartis | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Braeburn Inc. | 1 | $33 |
| Averitas Pharma Inc. | 1 | $28 |
| Baxter Healthcare | 1 | $27 |
| Medtronic | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Indivior Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Alkermes, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Exact Sciences | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
| Phadia US Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,148 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 95 | $117,426 |
| OzempicSemaglutide | 67 | $80,592 |
| RybelsusSemaglutide | 36 | $61,545 |
| FarxigaDapagliflozin Propanediol | 58 | $60,455 |
| EliquisApixaban | 69 | $56,288 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $52,512 |
| EntrestoSacubitril/Valsartan | 49 | $48,176 |
| MounjaroTirzepatide | 47 | $48,074 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 51 | $45,942 |
| TrulicityDulaglutide | 35 | $41,368 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $37,710 |
| XareltoRivaroxaban | 27 | $33,483 |
| LinzessLinaclotide | 30 | $27,589 |
| MyrbetriqMirabegron | 32 | $22,161 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $16,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy | $226 | $184,410178 claims |
| Novo NordiskOzempic, Rybelsus | $277 | $142,137103 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $174 | $61,27992 claims |
| AstraZenecaFarxiga | $241 | $60,45558 claims |
| PfizerEliquis | $99 | $56,28869 claims |
| NovartisEntresto | $37 | $48,17649 claims |
| Johnson & JohnsonXarelto | $92 | $33,48327 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $36 | $16,49217 claims |
| MerckJanuvia | $91 | $11,46315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Wynne
- Glenn GibbonsFort Smith$179K
- Hetal PatelParagould$147K
- David GersonSherwood$119K
- Scott MusickBentonville$102K
- Craig LevoyBentonville$30K
- Allen BeachyFort Smith$21K
- Hunter CarringtonHot Springs$20K
- Harold BettonLittle Rock$18K
- Thad HardinConway$18K
- Michael BerryNorth Little Rock$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.